Progress Toward Long-Term Survivors of Glioblastoma

J. Nathan Cantrell, Mark R. Waddle, Maarten Rotman, Jennifer L. Peterson, Henry Ruiz-Garcia, Michael G. Heckman, Alfredo Quinones-Hinojosa, Steven Rosenfeld, Paul D. Brown, Daniel Trifiletti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.

Original languageEnglish (US)
Pages (from-to)1278-1286
Number of pages9
JournalMayo Clinic proceedings
Volume94
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Glioblastoma
Survivors
Survival
Logistic Models
Brain Stem Neoplasms
Therapeutics
Comorbidity
Neoplasms
Radiotherapy
Clinical Trials
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cantrell, J. N., Waddle, M. R., Rotman, M., Peterson, J. L., Ruiz-Garcia, H., Heckman, M. G., ... Trifiletti, D. (2019). Progress Toward Long-Term Survivors of Glioblastoma. Mayo Clinic proceedings, 94(7), 1278-1286. https://doi.org/10.1016/j.mayocp.2018.11.031

Progress Toward Long-Term Survivors of Glioblastoma. / Cantrell, J. Nathan; Waddle, Mark R.; Rotman, Maarten; Peterson, Jennifer L.; Ruiz-Garcia, Henry; Heckman, Michael G.; Quinones-Hinojosa, Alfredo; Rosenfeld, Steven; Brown, Paul D.; Trifiletti, Daniel.

In: Mayo Clinic proceedings, Vol. 94, No. 7, 01.07.2019, p. 1278-1286.

Research output: Contribution to journalArticle

Cantrell, JN, Waddle, MR, Rotman, M, Peterson, JL, Ruiz-Garcia, H, Heckman, MG, Quinones-Hinojosa, A, Rosenfeld, S, Brown, PD & Trifiletti, D 2019, 'Progress Toward Long-Term Survivors of Glioblastoma', Mayo Clinic proceedings, vol. 94, no. 7, pp. 1278-1286. https://doi.org/10.1016/j.mayocp.2018.11.031
Cantrell JN, Waddle MR, Rotman M, Peterson JL, Ruiz-Garcia H, Heckman MG et al. Progress Toward Long-Term Survivors of Glioblastoma. Mayo Clinic proceedings. 2019 Jul 1;94(7):1278-1286. https://doi.org/10.1016/j.mayocp.2018.11.031
Cantrell, J. Nathan ; Waddle, Mark R. ; Rotman, Maarten ; Peterson, Jennifer L. ; Ruiz-Garcia, Henry ; Heckman, Michael G. ; Quinones-Hinojosa, Alfredo ; Rosenfeld, Steven ; Brown, Paul D. ; Trifiletti, Daniel. / Progress Toward Long-Term Survivors of Glioblastoma. In: Mayo Clinic proceedings. 2019 ; Vol. 94, No. 7. pp. 1278-1286.
@article{9ae0368d0b384c90939b7e6857b371f9,
title = "Progress Toward Long-Term Survivors of Glioblastoma",
abstract = "Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6{\%}) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.",
author = "Cantrell, {J. Nathan} and Waddle, {Mark R.} and Maarten Rotman and Peterson, {Jennifer L.} and Henry Ruiz-Garcia and Heckman, {Michael G.} and Alfredo Quinones-Hinojosa and Steven Rosenfeld and Brown, {Paul D.} and Daniel Trifiletti",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.mayocp.2018.11.031",
language = "English (US)",
volume = "94",
pages = "1278--1286",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Progress Toward Long-Term Survivors of Glioblastoma

AU - Cantrell, J. Nathan

AU - Waddle, Mark R.

AU - Rotman, Maarten

AU - Peterson, Jennifer L.

AU - Ruiz-Garcia, Henry

AU - Heckman, Michael G.

AU - Quinones-Hinojosa, Alfredo

AU - Rosenfeld, Steven

AU - Brown, Paul D.

AU - Trifiletti, Daniel

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.

AB - Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.

UR - http://www.scopus.com/inward/record.url?scp=85067548238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067548238&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.11.031

DO - 10.1016/j.mayocp.2018.11.031

M3 - Article

C2 - 31230743

AN - SCOPUS:85067548238

VL - 94

SP - 1278

EP - 1286

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -